Kaposi sarcoma associated herpesvirus (KSHV) reprograms cells upon infection. One other outcome of this reprogramming is cellular transformation, such that KSHV-infected cells give rise to human cancer. KSHV causes cancers of two different cell lineages: B cells and endothelial cells. KSHV reprograms endothelial cells to adopt a lymphatic phenotype and induces hyperplasia of these lymphatic endothelial cells. This eventually leads to the emergence of Kaposi sarcoma (KS). KSHV reprograms B cells, though it is unclear exactly which subset and what the direct outcome is. Eventually this, too, leads to complete transformation and the emergence of signature, KSHV-associated, B cell cancers, i.e. a subclass of multicentric Castleman's disease (MCD) and primary effusion lymphoma (PEL). We hypothesize that this reprogramming is mediated, at least in part, by viral and cellular micro RNAs. We previously identified KS specific cellular miRNAs and we will investigate their regulation in KS biopsies and culture models. We generated in KSHV miRNA transgenic mice and will investigate their phenotypes with regard to B cell function and oncogene cooperation.
This is application to continue our work on understanding the principal latent genes of Kaposi sarcoma associated herpesvirus (KSHV). KSHV causes cancers in the context of HIV/AIDS and the viral latent genes in particular the viral mirRNAs exhibit oncogenic properties. Understanding their function and regulation will help unravel the biology of cancers causes by KSHV and, we hope, provide novel targets for intervention.
|DeKroon, Robert M; Gunawardena, Harsha P; Edwards, Rachel et al. (2018) Global Proteomic Changes Induced by the Epstein-Barr Virus Oncoproteins Latent Membrane Protein 1 and 2A. MBio 9:|
|Nicholls, Thomas J; Nadalutti, Cristina A; Motori, Elisa et al. (2018) Topoisomerase 3? Is Required for Decatenation and Segregation of Human mtDNA. Mol Cell 69:9-23.e6|
|El-Mallawany, Nader Kim; Kamiyango, William; Villiera, Jimmy et al. (2018) Proposal of a Risk-Stratification Platform to Address Distinct Clinical Features of Pediatric Kaposi Sarcoma in Lilongwe, Malawi. J Glob Oncol :1-7|
|Selitsky, Sara R; Marron, David; Mose, Lisle E et al. (2018) Epstein-Barr Virus-Positive Cancers Show Altered B-Cell Clonality. mSystems 3:|
|Hosseinipour, Mina C; Kang, Minhee; Krown, Susan E et al. (2018) As-Needed Vs Immediate Etoposide Chemotherapy in Combination With Antiretroviral Therapy for Mild-to-Moderate AIDS-Associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical Trial. Clin Infect Dis 67:251-260|
|Lyons, Danielle E; Yu, Kuan-Ping; Vander Heiden, Jason A et al. (2018) Mutant Cellular AP-1 Proteins Promote Expression of a Subset of Epstein-Barr Virus Late Genes in the Absence of Lytic Viral DNA Replication. J Virol 92:|
|Bigi, Rachele; Landis, Justin T; An, Hyowon et al. (2018) Epstein-Barr virus enhances genome maintenance of Kaposi sarcoma-associated herpesvirus. Proc Natl Acad Sci U S A 115:E11379-E11387|
|El-Mallawany, Nader Kim; Villiera, Jimmy; Kamiyango, William et al. (2018) Endemic Kaposi sarcoma in HIV-negative children and adolescents: an evaluation of overlapping and distinct clinical features in comparison with HIV-related disease. Infect Agent Cancer 13:33|
|Kobayashi, E; Aga, M; Kondo, S et al. (2018) C-Terminal Farnesylation of UCH-L1 Plays a Role in Transport of Epstein-Barr Virus Primary Oncoprotein LMP1 to Exosomes. mSphere 3:|
|Hopcraft, Sharon E; Pattenden, Samantha G; James, Lindsey I et al. (2018) Chromatin remodeling controls Kaposi's sarcoma-associated herpesvirus reactivation from latency. PLoS Pathog 14:e1007267|
Showing the most recent 10 out of 324 publications